News

Article

Generic Drug Super Office Takes Shape

Author(s):

Generic Drug Super Office Takes Shape

The Office of Generic Drugs (OGD) is readying for its shift to a larger and more complex organization on par with offices for new drugs, drug safety, and compliance in FDA’s Center for Drug Evaluation and Research (CDER). Under the new generic drug user fee program (GDUFA), OGD is expanding its staff, working through a massive backlog of abbreviated new drug applications (ANDAs) and prior approval supplements, and assessing the completeness of drug master files in addition to evaluating more ANDAs and supplements.

The expanded OGD will have a strong clinical presence to assess bioequivalence and other tests, explained OGD acting director Kathleen Uhl at the Generic Pharmaceutical Association’s technical conference in October. An office of research will carry out studies to support development of more complex generic dosage forms, while an office of generic drug policy will develop guidance and internal procedures, Uhl noted. Chemists and microbiologists will join the new Office of Pharmaceutical Quality (OPQ), when it is established next year to unify the oversight of manufacturing and quality performance for all drugs, including biotech therapies.  

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content